

ANTI-INFLAMMATORY POTENTIAL OF *ALOE VERA* IN ORAL MUCOSITIS THERAPY: SYSTEMATIC REVIEW

VERRELY CHRISTIAN CHANDRA¹, NANAN NUR'AENY², INDAH SUASANI WAHYUNI^{2*}

¹Bachelor Program in Dentistry, Faculty of Dentistry, Universitas Padjadjaran, Indonesia, ²Department of Oral Medicine, Faculty of Dentistry, Universitas Padjadjaran, Indonesia
Email: indah.wahyuni@fkg.unpad.ac.id

Received: 17 Apr 2021, Revised and Accepted: 31 May 2022

ABSTRACT

This review aims to analyse the potency of *Aloe vera* for Oral Mucositis (OM) therapy. Articles searched using the keywords "Oral Mucositis" AND "*Aloe vera*", conducted through PubMed, ScienceDirect, and Cochrane Library databases, and adapted to the PICO (Population, Intervention, Comparison, Outcome) framework. The inclusion criteria for articles were: Randomized Controlled Trial (RCT) study design; in English; full paper available; published in the range between 2011-2021 and with low risk of bias. RoB-tools JADAD Oxford Quality Scoring System was used. This paper writing refers to the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) guidelines. A total of 5 (five) articles met the criteria for a qualitative review and all showed a high range of quality articles. It was found that both *Aloe vera* solution 70% and *Aloe vera* gel 10% showed a reduction of radiotherapy or chemotherapy-induced oral mucositis grade. *Aloe vera* mouthwash has an equal anti-inflammation effect compare to benzydamine on the patient with radiotherapy-induced oral mucositis, whereas the use of other formula containing *Aloe vera* with other herbal materials did not show an anti-inflammatory effect. Drug formulation containing *Aloe vera* can be used as an alternative therapy in the management of Oral Mucositis (OM) with anti-inflammatory potency that can reduce pain and the severity of oral mucositis.

Keywords: *Aloe vera*, Anti-inflammation, Oral mucositis

© 2022 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (<https://creativecommons.org/licenses/by/4.0/>)
DOI: <https://dx.doi.org/10.22159/ijap.2022.v14ti.21> Journal homepage: <https://innovareacademics.in/journals/index.php/ijap>

INTRODUCTION

Oral Mucositis (OM) is a toxic side effect of chemotherapy and/or radiotherapy treatment for malignancy/cancer [1]. The clinical feature of OM in the form of erosion and ulceration lesions on the oral mucosa that are usually widespread and painful, thus causing problems related to basic psychological needs such as chewing and swallowing food and can directly or indirectly affect a person quality of life [1]. OM involves a variety of complex biological interactions, such as: changes in tissue structure, infiltration of inflammatory cells, and oral microbiome [2]. It is estimated that 40-70% of patients who are undergoing chemotherapy and/or radiotherapy will experience OM with varying levels accompanied by clinical features that also varies [3, 4]. OM can also cause complications such as dysphagia, changes in taste, weight loss, and the appearance of secondary infections [5]. These complications can disrupt the schedule of cancer treatment so inadequate and complicate or extend the treatment time for malignancy conditions/cancer suffered [5].

Based on these problems, the therapy recommended according to the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) for OM is currently in the form of basic oral care. Therapies that use growth factors and cytokines, cryotherapy, photobiomodulation, anti-inflammatory drugs, anti-microbial drugs, coating agents, anesthetics, analgesics, and various natural ingredients are some of the basic oral care [6]. Steroids are also one of the drugs used as therapies for OM, but their use has several side effects [7]. This causes the scientist to look for steroid replacement alternatives with other drugs with equivalent but more potential, few or no side effects [7]. Currently, herbal products are being widely researched and used with therapeutic purposes because they are considered more economical, relatively safe, and generally have low toxicity [8]; however, the effectiveness and safety of these herbal medicines still need to be scientifically proven before they can be used to prevent or treat disease [9, 10].

Among these herbal products is *Aloe vera* (*Aloe barbadensis miller*) which is a shrub-like plant, can survive for years, xerophyte, succulent, and green in colour. *Aloe vera* belongs to the family Asphodelaceae (Liliaceae) [11]. All types of *Aloe vera* (AV) contain

gels that have more than 70 biological compounds with various properties such as anti-inflammatory, antimicrobial, antioxidant, antidiabetic, wound healing, immune system enhancer [12], antiviral, and anticancer [13]. This plant includes types of plants that are easy to grow and do not require special care. AV can grow in areas at altitudes of 0-1500 meters above sea level, air temperatures range from 16 °C-33 °C, and rainfall of 1000-3000 mm per year [14].

Until now, there have been several clinical trials on the use of *Aloe vera* as an OM therapy [15-20], as well as the writing of systematic review published in 2016, on the clinical effectiveness of *Aloe vera* in the management of oral mucosal disease [21] and systematic review published in 2021 on the effectiveness and safety of herbal plants for oral mucositis therapy [22], but the two did not discuss specifics regarding *Aloe vera* therapy for OM. Based on this, the writing of this review is intended to specifically discuss the potential and therapeutic response of using *Aloe vera* as an OM therapy so that it can be the basis of treatment (evidenced-based) for OM therapy scientifically.

MATERIALS AND METHODS

This article is a systematic review compiled following the guidelines of Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) [23]. Research questions are determined according to the purpose of writing, guided by the PICO (Population, Intervention, Comparison, and Outcome) [24] framework as follows: (1) Population: patients with Oral Mucositis (OM) diagnosis; (2) Intervention: *Aloe vera*; (3) Comparison: placebo and conventional therapy; (4) Outcome: (a) Subjective parameters of assessing pain; (b) Objective assessment parameters using the World Health Organization-Oral Mucositis (WHO-OM) grading system; (c) Complication parameters: dysphagia, nasogastric tube placement, intravenous hydration, need of supportive drugs, weight loss, and interruption of radiotherapy; (d) Side effects. The search method for research questions was conducted using the keywords "Oral Mucositis" AND "*Aloe vera*" Filters: Full text, Randomized Controlled Trial, in the last 10 y, Humans, English. The digital data bases used are: PubMed, Science Direct, and Cochrane Library. Additional article searches are also done manually by checking the list of article references that have been obtained, will be used if relevant to the research topic and have good article quality.

The inclusion criteria in this study are articles discussing the use of *Aloe vera* for oral mucositis (OM) therapy, is a clinical trial study with the design randomized controlled trial (RCT), in English, the full text is accessible, the subject of human research, published in the last 10 y (2011-2021), and has a low risk of bias (RoB) or good article quality. The article's screening and eligibility test are conducted by VCC and ISW. Articles resulting from the screening process using the inclusion criteria are assessed using the RoB-tools JADAD Oxford Quality Scoring System [25]. Oxford Quality Scoring System consists of five question points as stated in table 1. The maximum number of points is 5 and the minimum number of point's is-2. The number of points ≥ 3 shows articles with a high range of quality, while when the number of points ≤ 2 shows articles with a low range of quality [22, 25-27]. If there is a disagreement, a joint consensus will be made to determine the use of related articles.

Data extraction according to the expected outcome is carried out on all selected articles. Articles are analysed using qualitative thematic

analysis. The analysis is done by identifying, grouping, and analysing data from articles based on the similarity of themes found [28].

RESULTS

A total of 6 articles were filtered through searches in the PubMed database (identified 35 articles), 28 articles in the Science Direct database (identified 194 articles), and 21 articles in the Cochrane library database (identified 24 articles). A total of 2 additional articles were manually identified from the selected article bibliography, bringing the total of 57 filtered articles. Furthermore, a total of 51 articles have been excluded because they are not in accordance with the purpose of the study, so as many as 6 articles were tested using the JADAD Oxford Quality Scoring System. A total of 5 articles in the high range of quality and can be reviewed qualitatively, and 1 article is excluded because it is in the low range of quality. Fig. 1 show a flow chart of search results and article selection in this study.




Fig. 1: PRISMA flowchart of this systematic review

Table 1: Assessment of the risk of bias using the oxford quality scoring system

Reference	Question No.					Result
	(1)	(2)	(3)	(4)	(5)	
(Alkhouli, Laflouf and Alhaddad,2021) [15]	1	1	1	1	1	High range of quality
(Alkhouli, Laflouf and Comisi,2021) [16]	1	1	1	1	1	High range of quality
(Sahebjamee et al., 2015) [17]	1	1	1	1	1	High range of quality
(Mansouri et al., 2016) [18]	1	1	0	-1	1	Low range of quality
(Marucci et al., 2017) [19]	1	1	1	1	1	High range of quality
(Lakhani et al., 2017) [20]	1	1	1	1	1	High range of quality

Note: Question No. 1. Was the study described as random? (Yes = 1, No = 0); 2. Was the randomization scheme described and appropriate? (Yes = 1, No = -1); 3. Was the study described as double-blind? (Yes = 1, No = 0); 4. Was the method of double-blinding appropriate? (Yes = 1, No = -1); 5. Was there a description of dropouts and withdrawals? (Yes = 1, No = 0)

Table 2: General summary of reviewed articles

No	Title	Reference	Country	Subject of research	Drug formula
1	Efficacy of Aloe-Vera Use for Prevention of Chemotherapy Induced Oral Mucositis in Children with Acute Lymphoblastic Leukemia: A Randomized Controlled Clinical Trial	(Alkhouli, Laflouf and Alhaddad, 2021) [15]	Syria	26 patient: - 13 patient intervention group - 13 patient control group	Solution
2	Assessing the topical application efficiency of two biological agents in managing chemotherapy-induced oral mucositis in children: A randomized clinical trial	(Alkhouli, Laflouf and Comisi, 2021) [16]	Syria	36 patient: - 24 patient intervention group (12 patient of <i>Aloe vera</i> group, 12 patient of Olive oil group) - 12 patient control group	Solution
3	Comparative Efficacy of <i>Aloe vera</i> and Benzydamine Mouthwashes on Radiation-induced Oral Mucositis: A Triple-blind, Randomized, Controlled Clinical Trial	(Sahebamee <i>et al.</i> , 2015) [17]	Iran	26 patient: - 13 patient intervention group - 13 patient control group	Mouthwash
4	Double-blind randomized phase III study comparing a mixture of natural agents versus placebo in the prevention of acute mucositis during chemoradiotherapy for head and neck cancer	(Marucci <i>et al.</i> , 2017) [19]	Italy	104 patient: - 53 patient intervention group - 51 patient control group	Mouthwash
5	Efficacy of <i>Aloe vera</i> gel topical application on Radiation Induced Mucositis in Head and Neck Malignancy: A Double-blind, Randomized Clinical trial	(Lakhani <i>et al.</i> , 2017) [20]	India	100 patient: - 51 patient intervention group - 49 patient control group	Gel

Table 3: Result and outcome

No	Reference	Population	Intervention	Parameter outcome	Result
1	(Alkhouli, Laflouf and Alhaddad, 2021) [15]	Chemotherapy Induced Oral Mucositis (CIOM)	70% <i>Aloe vera</i> solution+potassium sorbate 0.1% preservatives and sodium meta-bisulfate 0.01%. Comparison: Sodium bicarbonate Intervention: Topical application of 5 ml, 2x a day on the tongue, the base of the mouth, buccal and labial mucosa, and lips	1. Subjective 2. Objective	1. <i>Aloe vera</i> solution 70% decreasing stomatitis intensity and pain. 2. <i>Aloe vera</i> solution 70% was better at lowering the severity of OM compared to the sodium bicarbonate group in the 2nd, 3rd, 4 th , and 7 th weeks. 3. <i>Aloe vera</i> solution 70% slows down OM better compared to sodium bicarbonate significantly
2	(Alkhouli, Laflouf and Comisi, 2021) [16]	Chemotherapy Induced Oral Mucositis (CIOM)	70% <i>Aloe vera</i> solution+potassium sorbate 0.1% preservatives and sodium meta-bisulfate 0.01%, Comparison: Olive oil and Sodium bicarbonate Intervention: Topical application 4x a day on the tongue, the base of the mouth, buccal and labial mucosa, and lips	Objective	1. <i>Aloe vera</i> solution 70% lowers the OM grading from Grade 3 into Grade 2. 2. Olive oil lowers the OM grading from Grade 4 into Grade 0. 3. <i>Aloe vera</i> dan olive oil were effective in the management of OM than sodium bicarbonate. 4. Significant statistical differences in mucositis degree before and after the use of <i>Aloe vera</i> and olive oil compared to the sodium bicarbonate group.
3	(Sahebamee <i>et al.</i> , 2015) [17]	Radiation Induced Oral Mucositis (RIOM)	<i>Aloe vera</i> mouthwash (Pure <i>Aloe vera</i> gel/Barij <i>Aloe vera</i> Syrup+0.0009% Brilliant Blue dye+0.0006% tartrazine yellow dye) Comparison: Benzydamine. Intervention: Gargle 5 ml, 3x a day	1. Objective 2. Side effect	1. Early signs of mucositis appear after 15.6 d (<i>Aloe vera</i> mouthwash) and after 15.7 (benzydamine). 2. Maximum mucositis grade occurrence was 23.3 d (<i>Aloe vera</i> mouthwash) and 23.5 d (benzydamine). 3. <i>Aloe vera</i> and benzydamine mouthwash decreased the onset of mucositis and the maximum onset of mucositis, but there was no significant statistical difference in the appearance of mucositis signs. 4. <i>Aloe vera</i> mouthwash caused nausea side effect in 2 patients (15.4%).
4	(Marucci <i>et al.</i> , 2017) [19]	Concomitant chemoradiotherapy	Faringel (<i>Propolis</i> powder extract 6% 8.7g, <i>Aloe vera</i> gel 30% 2.6g, <i>Calendula</i> powder extract 2% 12.0g, and <i>Chamomile</i> aqueous solution 0.3% 19.2g) Comparison: Placebo Intervention: Gargle 7 ml, 4x the day before meals and radiotherapy sessions	1. Subjective 2. Objective 3. Complication	1. Faringel cannot prevent severe or higher pain. 2. Faringel cannot prevent the development of grade 3 mucositis during chemoradiotherapy. 3. Faringel cannot prevent patients from using nasogastric feeding tube, intravenous hydration, and the occurrence of dysphagia
5	(Lakhani <i>et al.</i> , 2017) [20]	Radiation Induced Oral Mucositis (RIOM)	10% <i>Aloe vera</i> gel Comparison: Base gel Intervention: Topical application 3x a day	1. Subjective 2. Objective 3. Complication	1. <i>Aloe vera</i> gel can slow the progression of OM and reduce pain during radiotherapy. 2. <i>Aloe vera</i> gel can lower the severity of OM compared to the control group significantly. 3. <i>Aloe vera</i> gel reduces and slows the use of supportive drugs, reduced weight loss, reduced need of radiotherapy feeding, and improves quality of life.

Table 2 shows a general summary of the reviewed article. All articles have a Randomized Controlled Trial (RCT) study design. The study was conducted on Syria [15, 16], Iran [17], Italy [19], and India [20]. The number of study subjects consisted of 26 to 104 oral mucositis patients for each article with equal comparison control. *Aloe vera* preparations used in the study in the form of solution [15, 16], mouthwash [17, 19], and gel [20].

Table 3 shows the results of *Aloe vera* effectiveness in the management and prevention of oral mucositis induced by radiation [17, 20], chemotherapy [15, 16], or chemoradiotherapy [19]. The effectiveness of *Aloe vera* is determined based on several parameters and compares it with control groups such as conventionally used therapies such as sodium bicarbonate [15, 16] and benzydamine [17], placebo [19], and base gel [20]. Outcome parameters used to assess oral mucositis in the study were subjective, objective, complications, and side effects. Pain assessment parameters use Verbal Descriptor Scale (VDS) [19] and Visual Analogue Scale (VAS) [20].

DISCUSSION

Oral mucositis refers to a painful erythema and ulceration lesion in the oral mucosa of cancer patients undergoing chemotherapy and/or radiotherapy [29]. The acute mucosa inflammation begins as a reddish color and develops into ulceration and forms a pseudomembrane that acts as a temporary dividing wall until cellular tissue performs the wound healing process [30]. Damaged mucosa tissue often causes bacteria and fungi to multiply on the mucosa and causes secondary infection [30, 31].

Steroids are one of the drugs used as a therapy for various oral diseases today, but because of some of the side effects caused, herbal medicines began to be widely researched and considered as alternative therapies that can be used to prevent and treat diseases [7, 9, 10]. *Aloe vera* becomes one of the alternative therapies that can be used to treat various types of diseases because of its therapeutic potential as an immunostimulatory, anti-inflammatory, antioxidant, antibacterial, antifungal, radioprotective, and accelerate wound healing [32]. *Aloe vera* properties such as immunomodulators, anti-inflammatory, and antioxidants [12] can be used to treat local inflammation in the form of ulceration and antimicrobial, antiviral, and antifungal [32] properties can be used to treat secondary infections on the inflamed oral mucosa mainly caused by *Candida albicans* or *Herpes simplex* virus type 1 [33]. Oral Mucositis is usually followed by a bacterial or fungal infection of the oral cavity, so if herbal medicines have the same ability, then this is very useful for oral mucositis therapy.

Our review found that research related to *Aloe vera* as an anti-inflammatory for Oral Mucositis (OM) has been conducted in Asian countries and one Europe continent. A total of four articles state that *Aloe vera* is safe and effective in slowing and alleviating [17, 20], as well as preventing [15, 16] the development and severity of oral mucositis induced by radiotherapy and/or chemotherapy when compared to conventional therapy. The results from objective assessment of the severity of oral mucositis with WHO OM grading system conducted in four research articles showed a decrease in pain intensity and onset of mucositis. One research article found that *Aloe vera* formulations along with other herbal ingredients could not prevent oral mucositis when compared to placebo [19]. *Aloe vera* can prevent the severity of OM better than it does to prevent the appearance of OM. OM until now is still a side effect of chemotherapy and/or radiotherapy as a malignancy therapy/cancer that is difficult to avoid [34].

Most research articles mention *Aloe vera* as an empirical anti-inflammatory in traditional medicine and in *in vitro* studies are able to protect the skin and accelerate wound healing. *Aloe vera*'s active compounds aloesin, aloin, and emodin show their pharmacological effects through antioxidant and anti-inflammatory mechanisms [35]. Emodin is an inhibitor to the inflammatory response that causes decreased production of prostaglandins E₂ (PGE₂) and Cyclooxygenase-2 (COX-2) mRNA, known as biomarkers of inflammation [36]. Other active compounds contained in *Aloe vera* such as acemannan as a polysaccharide have the potential as immunostimulatory, anti-inflammatory, antioxidants, and accelerate wound healing [32]. *Aloe* polysaccharides can be a beneficial agent

in wound healing and inflammatory activities as they can inhibit the production of TNF- α , IL-8, and IL-12, which are pro-inflammatory cytokines in human keratinocytes [35].

Aloe vera extract in *in vivo* research is often used in gel preparations. Topical application of *Aloe vera* can demonstrate wound healing effects in animals induced with skin incisions indicated by reduced inflammatory cell infiltration parameters, increased CD4+/CD8+lymphocyte ratio, and increased epidermis thickness as well as collagen deposition [35]. Wound healing mechanisms are associated with polysaccharide compounds contained in *Aloe vera*. Polysaccharides can increase the proliferation of fibroblast growth factors, collagen production and strengthen connections among collagen tissue structures at the site of the wound [37, 38]. Research on radiation-induced rat oral mucosal ulceration shows that the use of *Aloe vera* and silver nanoparticles (AgNPs) can improve ulceration healing by restoring epithelial tissue and decreasing inflammatory cell infiltration [39]. Mucoadhesive gel preparations are generally more effective for oral mucosal ulceration lesion therapy [40], but mostly in all the articles we reviewed *Aloe vera* was tested in the form of mouthwash or solution preparations. The use of mouthwash preparations for OM therapy will be more effective to cover a large area of lesions [41], while the gel will be more effective because it can be directly registered on localized lesions [42].

Administration of *Aloe vera* mouthwash can cause a decrease in the onset of oral mucositis, decrease in the maximum onset severity of oral mucositis although not significant [17], or a significant decrease in oral mucositis degrees [15]. Alkhouli *et al.*, research with *Aloe vera* solution preparations showed a decrease in the severity of mucositis from grade 3 to grade 2, while the administration of intervention using olive oil showed a better decrease in the degree of mucositis and significantly from grade 4 to grade 0 [16]. Two patients were found to have nausea as an intervention side effect in the group given *Aloe vera* [17].

Aloe vera gel research shows a slowing of oral mucositis progression and reduced pain during radiotherapy. The secondary assessment showed a positive correlation in the use of *Aloe vera*, which can improve the quality of life [20]. However, article that tested the administration of mouthwash preparations containing *Aloe vera* gel along with three other herbal components, namely *Propolis*, *Calendula*, and *Chamomile* (Faringel), it was reported that no preventive effect of the preparation was found on the development of oral mucositis during chemoradiotherapy. This is still unexplained the reason, but it is estimated that the dose of natural ingredient use, or the possibility of interference with the wound healing process in patients, and the drug interactions that occur may be the causative factors [19].

Aloe vera mouthwash has anti-inflammatory effects equivalent to benzydamine in patients with radiotherapy-induced oral mucositis [17]. *Aloe vera* solution 70% can improve the condition of oral mucositis induced by chemotherapy [15, 16] and *Aloe vera* gel 10% can improve oral mucositis induced by radiotherapy [20]. *Aloe vera* solution with a concentration of 70% and gel 10%, both of which can reduce oral mucositis score. This effective concentration difference may be related to differences in *Aloe vera* extraction techniques, or differences in dosage forms, namely solutions and gels, or also due to differences in cancer therapy interventions received by patients, as well as the possible quantity of active metabolite content in different plants because they are grown in different countries as well. Environmental differences based on climate, temperature, rainfall, fertility, and soil moisture can also create plant variations that can affect plant growth phases, nutrients, and the content of plant secondary metabolites [43, 44].

Based on a review of these articles, we found a fairly high potential of *Aloe vera* as an alternative therapy that can be used for oral management because it can overcome inflammatory reactions in oral mucositis. Our current review complements the information of two previously published review discussions on the clinical effectiveness of *Aloe vera* in the management of oral mucosal disease [21] and in terms of the effectiveness and safety of herbal plants for oral mucositis therapy [22]. Thus, drug formulation containing *Aloe vera* can be recommended in OM management, especially in terms of reducing pain and severity of OM.

Limited information regarding the specific condition of the oral mucosa, differences in dosage form, and the amount of *Aloe vera* used can be one of the obstacles in comparing the effectiveness of *Aloe vera* in a balanced manner among the articles we reviewed. In addition, this review does not cover all parts of the continent in the world and only covers the continent of Asia and one European country, so it can be further recommended to conduct further clinical trials of drug preparations containing *Aloe vera* with various doses in more homogeneous populations in countries on the continent that have not been reached in this review, to strengthen its evidence-based use in OM therapy.

The results of this writing are expected to be evidence-based that supports consideration of clinical applications of the use of *Aloe vera*-based drug preparations for patients experiencing oral mucositis, can also be the basis of further research related to the development of *Aloe vera* as an anti-inflammatory in other inflammatory diseases of the oral mucosa, as well as research on the development of drug formulations.

CONCLUSION

Drug formulation containing *Aloe vera* can be used as an alternative therapy in the management of Oral Mucositis (OM) with anti-inflammatory potency that can reduce pain and the severity of oral mucositis.

ACKNOWLEDGEMENT

This manuscript writing is supported by Universitas Padjajaran and the part of the undergraduate thesis of Verrely Christian Chandra.

AUTHORS CONTRIBUTION

All the author have contributed equally

CONFLICTS OF INTERESTS

There are no conflicts of interest.

REFERENCES

- Kusiak A, Jereczek Fossa BA, Cichońska D, Alterio D. Oncological-therapy related oral mucositis as an interdisciplinary problem-literature review. *Int J Environ Res Public Health*. 2020 Apr 3;17(7):2464. doi: 10.3390/ijerph17072464, PMID 32260309, PMCID PMC7177874.
- Chen C, Zhang Q, Yu W, Chang B, Le AD. Oral mucositis: an update on innate immunity and new interventional targets. *J Dent Res*. 2020 Sep;99(10):1122-30. doi: 10.1177/0022034520925421. PMID 32479139, PMCID PMC7443999.
- Lalla RV, Peterson DE. Oral mucositis. *Dent Clin North Am*. 2005 Jan;49(1):167-84. doi: 10.1016/j.cden.2004.07.009. PMID 15567367.
- Normando AGC, de Meneses AG, de Toledo IP, Borges GA, de Lima CL, Dos Reis PED. Effects of turmeric and curcumin on oral mucositis: A systematic review. *Phytother Res*. 2019 May;33(5):1318-29. doi: 10.1002/ptr.6326. PMID 30838707.
- Daugėlaitė G, Uzkuraitytė K, Jagelavicienė E, Filipauskas A. Prevention and treatment of chemotherapy and radiotherapy induced oral mucositis. *Medicina (Kaunas)*. 2019 Jan 22;55(2):25. doi: 10.3390/medicina55020025, PMID 30678228, PMCID PMC6410239.
- Erratum to "MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy". *Cancer*. 2021;127(19):3700. doi: 10.1002/cncr.33549. PMID 34233011.
- Salehi B, Lopez Jornet P, Lopez PFE, Calina D, Sharifi Rad M, Ramirez Alarcon K, Forman K, Fernandez M, Martorell M, Setzer WN, Martins N, Rodrigues CF, Sharifi-Rad J. Plant derived bioactives in oral mucosal lesions: a key emphasis to curcumin, lycopene, chamomile, aloe vera, green tea and coffee properties. *Biomolecules*. 2019 Mar 17;9(3):106. doi: 10.3390/biom9030106. PMID: 30884918; PMCID: PMC6468600.
- Amjed S, Junaid K, Jafar J, Amjad T, Maqsood W, Mukhtar N. Detection of antibacterial activities of Miswak, Kalonji and *Aloe vera* against oral pathogens and anti-proliferative activity against cancer cell line. *BMC Complement Altern Med*. 2017 May 15;17(1):265. doi: 10.1186/s12906-017-1778-0, PMID 28506259, PMCID PMC5433005.
- Victor AD, Prasad M, Mohanasundaram S. Biological active compounds with various medicinal values of *Strychnos nuxvomica*-a pharmacological summary. *J Glob Trends Pharm Sci*. 2016;7(1):3044-7.
- Narendhiran S, Mohanasundaram S, Arun J, Saravanan L, Catherine L, Subathra M. Comparative study in larvicidal efficacy of medicinal plant extracts against *Culex quinquefasciatus*. *Int J Res Plant Sci*. 2014;4(1):22-5.
- Surjushe A, Vasani R, Sable DG. *Aloe vera*: a short review. *Indian J Dermatol*. 2008;53(4):163-6. doi: 10.4103/0019-5154.44785, PMID 19882025, PMCID PMC2763764.
- Bahrami G, Malekshahi H, Miraghaee S, Madani H, Babaei A, Mohammadi B. Protective and therapeutic effects of *Aloe vera* gel on ulcerative colitis induced by acetic acid in rats. *Clin Nutr Res*. 2020 Jul 30;9(3):223-34. doi: 10.7762/cnr.2020.9.3.223, PMID 32789152, PMCID PMC7402976.
- Gao Y, Kuok KI, Jin Y, Wang R. Biomedical applications of *Aloe vera*. *Crit Rev Food Sci Nutr*. 2019;59Suppl 1:S244-56. doi: 10.1080/10408398.2018.1496320. PMID 29999415.
- Mohanasundaram S, Victor AD, Prasad M, Magesh R, Sivakumar K, Subathra M. Pharmacological analysis of a hydroethanolic extract of *Senna alata* (L.) for *in vitro* free radical scavenging and cytotoxic activities against Hep G2 cancer cell line. *Pak J Pharm Sci*. 2019;32(3):931-4.
- Alkhouli M, Laflouf M, Alhaddad M. Efficacy of aloe-vera use for prevention of chemotherapy-induced oral mucositis in children with acute lymphoblastic leukemia: A randomized controlled clinical trial. *Compr Child Adolesc Nurs*. 2021 Mar;44(1):49-62. doi: 10.1080/24694193.2020.1727065. PMID 32101488.
- Alkhouli M, Laflouf M, Comisi JC. Assessing the topical application efficiency of two biological agents in managing chemotherapy-induced oral mucositis in children: a randomized clinical trial. *J Oral Biol Craniofac Res*. 2021 Jul-Sep;11(3):373-8. doi: 10.1016/j.jobcr.2021.04.001. PMID 33996432, PMCID PMC8093931.
- Mohanasundaram S, Rangarajan N, Sampath V, Porkodi K, Prakash MVD, Monicka N. GC-MS identification of anti-inflammatory and anticancer metabolites in edible milky white mushroom (*Calocybe indica*) against human breast cancer (MCF-7) cells. *Res J Pharm Technol*. 2021;14(8):4300-6.
- Mansouri P, Haghghi M, Beheshtipour N, Ramzi M. The effect of *Aloe vera* solution on chemotherapy-induced stomatitis in clients with lymphoma and leukemia: A randomized controlled clinical trial. *Int J Community Based Nurs Midwifery*. 2016 Apr;4(2):119-26. PMID 27218109, PMCID PMC4876780.
- Mohanasundaram S, Rangarajan N, Sampath V, Porkodi K, Pennarasi M. GC-MS and HPLC analysis of antilycogenolytic and glycogenic compounds in kaempferol 3-O-gentiobioside containing *Senna alata* L leaves in experimental rats. *Transl Metab Syndr Res*. 2021;4:10-7. doi: 10.1016/j.tmsr.2021.07.001.
- Lakhani R, Kshirsagar AY, Chedha R. Efficacy of *Aloe vera* gel topical application on radiation-induced mucositis in Head and Neck malignancy. Vol. 8 AD; 2017.
- Nair GR, Naidu GS, Jain S, Nagi R, Makkad RS, Jha A. Clinical effectiveness of *Aloe vera* in the management of oral mucosal diseases-A systematic review. *J Clin Diagn Res*. 2016 Aug;10(8):ZE01-7. doi: 10.7860/JCDR/2016/18142.8222, PMID 27656587, PMCID PMC5028429.
- Wahyuni IS, Sufiawati I, Nittayananta W, Puspitasari IM, Levita J. Efficacy and safety of plant-based therapy on recurrent aphthous stomatitis and oral mucositis in the past decade: a systematic review. *J HerbMed Pharmacol*. 2021 Jan 5;10(2):179-87. doi: 10.34172/jhp.2021.19.
- Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*. 2021 Mar 29;372:n71. doi: 10.1136/bmj.n71. PMID 33782057, PMCID PMC8005924.
- Victor AD, Mohanasundaram S, Prasad M. Analysis of hydroethanolic extract of *Senna alata* (L.) to screen bioactive compounds with inhibitory activity on lipid peroxidation, *in vitro* antibacterial and antidiabetic efficacy. *Int J Pharm Sci*. 2016;6(1):1360-6.

25. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? *Control Clin Trials*. 1996 Feb;17(1):1-12. doi: 10.1016/0197-2456(95)00134-4, PMID 8721797.
26. Augestad KM, Berntsen G, Lassen K, Bellika JG, Wootton R, Lindsetmo RO. Standards for reporting randomized controlled trials in medical informatics: a systematic review of CONSORT adherence in RCTs on clinical decision support. *J Am Med Inform Assoc*. 2012 Jan-Feb;19(1):13-21. doi: 10.1136/amiajnl-2011-000411. PMID 21803926, PMCID PMC3240766.
27. Mohanasundaram S, Doss VA, Haripriya G, Varsha M, Daniya S, Madhankumar. GC-MS analysis of bioactive compounds and comparative antibacterial potentials of aqueous, ethanolic and hydroethanolic extracts of *Senna alata* L. against enteric pathogens. *Int J Res Pharm Sci*. 2017;8(1):22-7.
28. Nowell LS, Norris JM, White DE, Moules NJ. Thematic analysis: striving to meet the trustworthiness criteria. *Int J Qual Methods*. 2017 Dec 2;16(1), doi: 10.1177/1609406917733847.
29. Daugėlaitė G, Uzkuraitytė K, Jagelavicienė E, Filipauskas A. Prevention and treatment of chemotherapy and radiotherapy induced oral mucositis. *Medicina (Kaunas)*. 2019 Jan 22;55(2):25. doi: 10.3390/medicina55020025, PMID 30678228, PMCID PMC6410239.
30. Aghamohamamdi A, Hosseinimehr SJ. Natural products for management of oral mucositis induced by radiotherapy and chemotherapy. *Integr Cancer Ther*. 2016 Mar;15(1):60-8. doi: 10.1177/1534735415596570. PMID 26306626, PMCID PMC5736079.
31. Lalla RV, Brennan MT, Gordon SM, Sonis ST, Rosenthal DI, Keefe DM. Oral mucositis due to high-dose chemotherapy and/or head and neck radiation therapy. *J Natl Cancer Inst Monogr*. 2019 Aug 1;2019(53):lgz011. doi: 10.1093/jncimonographs/lgz011, PMID 31425601.
32. Kumar R, Singh AK, Gupta A, Bishayee A, Pandey AK. Therapeutic potential of Aloe vera-A miracle gift of nature. *Phytomedicine*. 2019 Jul;60:152996. doi: 10.1016/j.phymed.2019.152996. PMID 31272819.
33. Rangarajan N, Sangeetha R, Mohanasundaram S, Sampath, Porkodi K, Dass Prakash MV. Additive inhibitory effect of the peels of *Citrus limon* and *Citrus sinensis* against amylase and glucosidase activity. *IJRPS* 2020;11(4):6876-80. doi: 10.26452/ijrps.v11i4.3661.
34. Lionel D, Christophe L, Marc A, Jean-Luc C. Oral mucositis induced by anticancer treatments: physiopathology and treatments. *Ther Clin Risk Manag*. 2006 Jun;2(2):159-68. doi: 10.2147/tcrm.2006.2.2.159, PMID 18360589, PMCID PMC1661654.
35. Sanchez M, Gonzalez Burgos E, Iglesias I, Gomez Serranillos MP. Pharmacological update properties of Aloe vera and its major active constituents. *Molecules*. 2020 Mar 13;25(6):1324. doi: 10.3390/molecules25061324, PMID 32183224, PMCID PMC7144722.
36. Park MY, Kwon HJ, Sung MK. Evaluation of aloin and aloe-emodin as anti-inflammatory agents in aloe by using murine macrophages. *Biosci Biotechnol Biochem*. 2009 Apr 23;73(4):828-32. doi: 10.1271/bbb.80714. PMID 19352036.
37. Teplicki E, Ma Q, Castillo DE, Zarei M, Hustad AP, Chen J. The effects of Aloe vera on wound healing in cell proliferation, migration, and viability. *Wounds*. 2018 Sep;30(9):263-8. PMID 30256753.
38. Ujjan JA, Morani W, Memon N, Mohanasundaram S, Nuhmani S, Singh BK. Force platform-based intervention program for individuals suffering with neurodegenerative diseases like Parkinson. *Comput Math Methods Med*. 2022. doi: 10.1155/2022/1636263, PMID 35082910.
39. El-Batal AI, Ahmed SF. Therapeutic effect of Aloe vera and silver nanoparticles on acid-induced oral ulcer in gamma-irradiated mice. *Braz Oral Res*. 2018 Feb 5;32:e004. doi: 10.1590/1807-3107bor-2018.vol32.0004. PMID 29412224.
40. Shaikh R, Raj Singh TR, Garland MJ, Woolfson AD, Donnelly RF. Mucoadhesive drug delivery systems. *J Pharm Bioallied Sci*. 2011 Jan;3(1):89-100. doi: 10.4103/0975-7406.76478, PMID 21430958, PMCID PMC3053525.
41. Krishnamurthy S, Vijayarathay S. Role of nanomaterials in clinical dentistry. *Nanobiomater Dent Appl Nanobiomater*. 2016 Jun 13;11:211-40.
42. Wang Q, Sivakumar K, Mohanasundaram S. Impacts of extrusion processing on food nutritional components. *Int J Syst Assur Eng Manag*. 2022;13(S1):364-74. doi: 10.1007/s13198-021-01422-2.
43. Kumar S, Yadav M, Yadav A, Yadav JP. Impact of spatial and climatic conditions on phytochemical diversity and *in vitro* antioxidant activity of Indian Aloe vera (L.) *Burm. f. S Afr J Bot*. 2017 Jul 1;111:50-9. doi: 10.1016/j.sajb.2017.03.012.
44. Wahyuni IS, Sufiawati I, Nittayananta W, Levita J. The determination of ethyl p-methoxy cinnamate in *Kaempferia galanga* l. Rhizome extract harvested in rainy and dry seasons. *Int J App Pharm*. 2021 Dec 11:132-5. doi: 10.22159/ijap.2021.v13s4.43841.